Armstrong, MD, MPH, chief of dermatology, UCLA, discusses clinical trial findings from the phase 2b study on zasocitinib.

Some patients with psoriasis who were treated with guselkumab and achieved complete skin clearance experienced a persistent impact on quality of life.

Basel, Switzerland Friday, September 20, 2024, 13:00 Hrs [IST] ...

The global psoriasis therapeutics market revenue was around US$ 25.0 billion in 2022 and is estimated to reach US$ 55.8 billion by 2031, growing at a compound annual growth rate (CAGR) of 9.3% during ...

Tremfya is now approved for the treatment of plaque psoriasis, active psoriatic arthritis and ulcerative colitis.

The Roivant company is dedicated to developing and commercializing innovative therapeutics in immune-dermatology.

New research reveals a genetic connection between cardiovascular disease and psoriasis, suggesting shared inflammatory ...

Organon & Co (NYSE:OGN) has agreed to acquire Roivant Sciences Ltd’s (NASDAQ:ROIV) Dermavant Sciences Ltd, which is focused ...

Alumis, a recent IPO, has ESK-001, a promising phase 3 TYK2 inhibitor for Psoriasis and SLE, showing superior efficacy and safety over existing treatments. ESK-001's allosteric inhibition offers high ...

Johnson & Johnson (NYSE: JNJ) has announced the FDA‘s approval of TREMFYA® (guselkumab) for adults with moderately to ...

The robot has provided surgeons with instruments that offer a greater range of movement than in conventional keyhole surgery State-of-the-art robotic surgery has helped improve treatment for ...

Experts at the Skin of Color Update today in New York City highlighted recent FDA-approved dermatological treatments and ...